Is Bright Minds Biosciences Inc. (DRUG) a Buy, Sell, or Hold?
NASDAQ : DRUG
Bright Minds Biosciences Inc.
$73.26 USD
-$1.37 (-1.84%)
- Volume
- 212.58K
- Average Volume
- 318.93K
- Market Capitalization
- $717.01M
- P/E Ratio
- -30.42
- Dividend Yield
- 0.00%
- Price Target
- $145.00
- Year High
- $123.75
- Year Low
- $32.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $81.48
Company Overview
NASDAQ
Ian McDonald
Biotechnology
Healthcare
DRUG
26
US
USD
Liquidity Metrics
0.00
81.48
81.48
80.76
0.00
Sales & Valuation
-$
0.00
3.22
-50.31
-2.09
Profitability
-$1.78
-$12.23M
0.00%
0.00%
-20.73%
-8.83%
P/E Metrics
-30.42
0.27
0.27
Analyst Price Target & Rating
$145.00
$220.00
$126.00
2/5
4 Analysts
-49.48%
Financial Health Scores
153.67
1/9
$308.24M
$312.15M
$3.83M
-$27.52M
Key Metrics (TTM)
$700.83M
0.00
-22.38
81.48
-20.73%
-10.20%
-2.78%
-1.99%
-25030 days
Company Executives
| Name | Title |
|---|---|
| Ian McDonald | Co-Founder, Chief Executive Officer, President & Director |
| Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer |
| Ryan E. S. K. Cheung | CFO & Corporate Secretary |
| Stephen D. Collins | Chief Medical Officer |
| Jan Torleif Pedersen | Chief Science Officer & Director |
| Emer Leahy | Consultant |
Poll Results
No votes yet today — be the first to share your view!
About Bright Minds Biosciences Inc. (NASDAQ:DRUG) Stock
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the ... Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Vistagen Appoints Douglas J. Williamson to its Board of Directors
2026-07-31 08:30:00
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.
2026-07-23 10:56:00
The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
2026-07-22 13:02:07
Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
2026-05-26 19:18:00
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
2026-05-21 17:31:11
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Frequently Asked Questions
-
What is the current Bright Minds Biosciences Inc. (DRUG) stock price?
-
Bright Minds Biosciences Inc.(NASDAQ:DRUG) stock price is $73.26 in the last trading session. During the trading session, DRUG stock reached the peak price of $123.75 while $32.5 was the lowest point it dropped to. The percentage change in DRUG stock occurred in the recent session was --1.84% while the dollar amount for the price change in DRUG stock was -$1.37.
-
DRUG's industry and sector of operation?
-
The NASDAQ listed DRUG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DRUG?
-
Ian McDonald | Co-Founder, Chief Executive Officer, President & Director
Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer
Ryan E. S. K. Cheung | CFO & Corporate Secretary
Stephen D. Collins | Chief Medical Officer
Jan Torleif Pedersen | Chief Science Officer & Director -
How many employees does DRUG have?
-
Number of DRUG employees currently stands at 26. DRUG operates from 19 Vestry Street, New York, NY 10013, US.
-
Link for DRUG official website?
-
Official Website of DRUG is: https://brightmindsbio.com
-
How do I contact DRUG?
-
DRUG could be contacted at phone #647 407 2515 and can also be accessed through its website. DRUG operates from 19 Vestry Street, New York, NY 10013, US.
-
How many shares of DRUG are traded daily?
-
The average number of DRUG shares traded daily for last 3 months was 318.93K.
-
What is the market cap of DRUG currently?
-
The market value of DRUG currently stands at $717.01M with its latest stock price at $73.26